Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.
Zahoor M, Westhrin M, Aass KR, Moen SH, Misund K, Psonka-Antonczyk KM, Giliberto M, Buene G, Sundan A, Waage A, Sponaas AM, Standal T. Zahoor M, et al. Among authors: Misund K. Blood Adv. 2017 Dec 13;1(27):2656-2666. doi: 10.1182/bloodadvances.2017010801. eCollection 2017 Dec 26. Blood Adv. 2017. PMID: 29296919 Free PMC article.
The duration of gastrin treatment affects global gene expression and molecular responses involved in ER stress and anti-apoptosis.
Selvik LK, Fjeldbo CS, Flatberg A, Steigedal TS, Misund K, Anderssen E, Doseth B, Langaas M, Tripathi S, Beisvag V, Lægreid A, Thommesen L, Bruland T. Selvik LK, et al. Among authors: Misund K. BMC Genomics. 2013 Jun 28;14:429. doi: 10.1186/1471-2164-14-429. BMC Genomics. 2013. PMID: 23805861 Free PMC article.
Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells.
Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A, Otterlei M. Müller R, et al. Among authors: Misund K. PLoS One. 2013 Jul 31;8(7):e70430. doi: 10.1371/journal.pone.0070430. Print 2013. PLoS One. 2013. PMID: 23936203 Free PMC article.
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T. Olsen OE, et al. Among authors: Misund K. Blood Cancer J. 2014 Mar 21;4(3):e196. doi: 10.1038/bcj.2014.16. Blood Cancer J. 2014. PMID: 24658374 Free PMC article.
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A. Rustad EH, et al. Among authors: Misund K. Blood Cancer J. 2015 Mar 20;5(3):e299. doi: 10.1038/bcj.2015.24. Blood Cancer J. 2015. PMID: 25794135 Free PMC article.
MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.
Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A. Holien T, et al. Among authors: Misund K. Oncotarget. 2015 Sep 8;6(26):22698-705. doi: 10.18632/oncotarget.4245. Oncotarget. 2015. PMID: 26087190 Free PMC article.
31 results
Jump to page